Last reviewed · How we verify
NCT06715124
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Phase 1 trial testing QTX3544 in Advanced Solid Tumors in 237 participants. Participants enrolled and being followed up; not accepting new ones.
2 January 2027
Quick facts
| Lead sponsor | Quanta Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 237 |
| Start date | 14 January 2025 |
| Primary completion | 2 January 2027 |
| Estimated completion | 2 January 2029 |
| Sites | 10 locations across United States |
Drugs / interventions tested
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Sponsor
Quanta Therapeutics — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Response and Resistance to RAS Inhibition in Cancer.
Ebright RY, Dilly J, Shaw AT, Aguirre AJ. · · 2025 · cited 16× · PMID 40293709 · DOI 10.1158/2159-8290.cd-25-0349 -
Mechanisms and current advances in treating <i>KRAS</i>-mutated lung cancer.
Chao CH, Di YP. · · 2025 · cited 1× · PMID 41114080 · DOI 10.1016/j.pccm.2025.08.001 -
Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions.
Peng C, Oberstein PE. · · 2025 · cited 1× · PMID 40884689 · DOI 10.1007/s11864-025-01352-2
Verify or expand the search:
- PubMed search for NCT06715124
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Quanta Therapeutics trials
Trials by the same sponsor.
- NCT06428500 — QTX3046 in Patients With KRAS G12D Mutations · Phase 1 · active not recruiting
- NCT06227377 — QTX3034 in Patients With KRAS G12D Mutation · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06715124 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Quanta Therapeutics
- Last refreshed: 2 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06715124.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing